Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Canes..."I've learned appeals are almost certainly a dead end. Although Marjac's was the strongest in my unprofessional opinion. I think it might have succeeded had Amarin been on board."
That decision was on PWO, who cared more about the interests of of Covington and Kennedy than about Amarin or Vascepa or patients.
When PWO sold all of Sofinnova's Amarin shares, he forfeited the right to be COB of Amarin....Denner's win in the proxy fight was a no-brainer.
I see no problem with Denner's team being awarded shares...Its when they start selling them. I get worried.
Capt...Thanks for the stats...Lipitor sells twice as much in the U.K. as all the other statins combined...It is an obvious choice for a FDC combo with EPA.
J.R....Don't your eye off the ball...Amarin is now for sale...and the best person to sell it is Denner....and the price will be higher than it is at present.
dogn..Thank you for posting this...The current Amarin web site can be difficult to navigate when you are looking to find a specific piece of news.
always..."Many bearish influencers have shown up lately."....Amarin is a low priced stock with relatively low volumes of shares changing hands each day....This makes Amarin an easy prey for those with a motive to pursue their desired result...Either on the buy side...or on the sell side....i.e. "talking your book"
We can learn from those "talking their book"...but should not be unduly influenced by them.
Tat...You forget that Denner's good reputation is the reason that he was able to take over Amarin...he's young and his reputation is worth a lot to him....This is not his last rodeo.
golf...Think of Amarin as a start up with lots of potential and us as venture capitalists...Amarin doesn't have to be "ripe" for us to cash out.
cbb..."Once pricing was determined in the world outside of the US, then the BP launches
a US branded generic"
Low prices for large volume purchases of EPA from wholesalers + low prices for large volume sales of a Vascepa authorized generic = significant profits for a BP and better health for patients....QED
Vaskepa can help reduce CVD in China.... As we know, smolking is a risk factor for CVD.
"There are more than 300 million smokers in China, nearly one-third of the world's total. More than half of adult men are current tobacco smokers. About one in every three cigarettes smoked in the world is smoked in China."
IMO Germany rejected Vaskepa because of the price....With the price lower...Germany will come around.
It would be interesting to see Vascepa being distributed to patients in China...and not in Germany, which is supposedly one of the world leaders in Scientific achievement.
Tat...Vaskepa is likely to be reimbursed in China, but probably at a lower price than the present price...It is in their patients' interest and in China's interest to have a reduction in CVD.
A...QUOTE.."On February 23, 2022, The Hong Kong Department of Health concluded their evaluation and approved the use of VASCEPA under the REDUCE-IT indication."
cbb...I agree that the milestone agreements could be amended, putting them off into the future...However, it is the idea of a newly increased volume of sales of Vascepa in China...along with royalty payments to Amarin, that is, IMO, even more deserving of attention.
cbb...Since Vascepa has a long history of being safe and effective for reduction of CVD in Europe, in the U.S., in Canada, and in ROW, approval for Vascepa for CVD in China should not take as long as did the China approval for the high triglyceride indication.
Amarin will be buying larger volumes of EPA and this will mean lower prices charged to Amarin by wholesalers.
Some details in the 2015 Amarin-Eddingpharm agreement ..."Terms of the agreement include up-front and milestone payments to Amarin of up to $169.0 million, including a non-refundable $15.0 million up-front payment and development, regulatory and sales-based milestone payments of up to an additional $154.0 million. Eddingpharm will also pay Amarin tiered double-digit percentage royalties on net sales of Vascepa in the territory escalating to the high teens. Amarin will supply product to Eddingpharm under negotiated supply terms."
IMO this approval in China introduces a new era for Vascepa, in which Vascepa can be sold in volume...even if the price has to be somewhat lower than previously maintained.
Bob...QUOTE...“We are glad to receive this regulatory approval of VASCEPA from the NMPA China, and we are looking forward to securing reimbursement for this important product for patients and to a future CVRR indication approval,” said Rebecca Xu, Vice President of Clinical Development, EDDING."
THIS IS HUGE!...The next vital information we need is about reimbursement.
Amarin already up in pre-market!
john..QUOTE.. "in the right hands would mean massive lawsuits against infringing parties with new gsk/teva precedent.".....
I assume that that by "in the right hands" you mean in the hands of a BP, which is able to afford a law firm to prosecute the infringement case....Perhaps Amarin could now entice a patent law firm to take this case on a contingency basis.
Hikma and Reddy, in an ongoing conspiracy with insurance companies, have openly infringed on Amarin's CVD patents and have already stolen millions of dollars that rightfully belonged to Amarin.
The last two days have been good for Pfizer... with the news about their blockbuster drug for weight loss and the renewed interest in their Covid vaccine.
I assume the increase in the market cap of their stock during these two days would be more than enough to fund a BO of Amarin.
My guess...I assume that Teva did not buy all that IPE in order to market their own generic to compete on the same basis with the other four already approved gV products...plus with Amarin's branded Vascepa
In order to make use of their inventory, Teva will need a large market...They will acquire Amarin and proceed to sell branded Vascepa at low prices in the U.S., Europe, and ROW....Teva will pay lower prices for their API because of their increased volume of purchases.
Teva will advertise and emphasize the superiority of their product over gV.
EPA is the term being used by Doctors more and more while Vascepa is being used less and less...Amarin should now drop the name Vascepa and call the product what it is...EPA PURE...unless someone has already trademarked that name.
Louie...good to hear from you again...
I have felt it is still possible that, with the current backing of Amarin management, a new appeal could be made to SCOTUS concerning the fraud in the judge DU ninth circuit case, which appeal might lead to a reexamination of judge Du's erroneous decision to invalidate Amarin's high triglyceride patent...and SCOTUS might accept the case for trial.
The Amarin-Teva agreement dealt ONLY with Amarin's High Trig patent...NOT with Amarin's CVD patent....If Teva's gV is used for the CVD indication, it will be infringing once again, as it did with Teva's skinny label in the GSK case, which cost them $285 million in damages
P...If that was the condition of the settlement, why would Healthnet have insisted that the terms of the agreement be kept secret?
P...The reason Healthnet settled the lawsuit was because they feared that they would have to pay a huge monetary award to Amarin for their infringement on Amarin's CVD patent.
P...Thank you for that astute analysis...This indicates to me that Amarin MUST come up with a product, which is better than gV, in order to avoid a race to the bottom on price....Perhaps a FDC with a statin plus MND-2119 could be that better product, especially if the need for Amarin to pay royalties to Mochida is not too burdensome...Thus far, we have been given no clues about that aspect of their "collaboration" contract.
Teva also markets generic Lovaza in addition to gV...and probably sells more gL than gV...even though they must be aware that generic Lovaza is a useless waste of patients' money for reducing CVD, which is the main indication patients are buying it for...Now Teva has decided to switch away from marketing generic drugs to being a marketer of branded drugs.
Teva totally lacks credibility...and IMO is as bad as Hikma and Dr. Reddy, who prey upon the public with bad, but slightly cheaper products.
This Scotus decision seems to be in line with a pattern of court decisions by conservative, as well as liberal, judges, to weaken patent protections.
This Amgen decision seems to be the tip of the iceberg of what is becoming a pattern of invalidation of patents altogether...The current theory is that...if you really don't fully understand the science or the history behind a patent, just make it go away.
Patent lawyers have to be scientists and teachers in addition to being litigators.
Average ages in most countries are trending to be older...There are bound to be more patients ,needing care for acute and chronic diseases...As medical expenditures by governments become more restrictive, expensive medicines that extend lives for a few months or years, such as cancer therapies, will necessarily be made less available to patients by governments which pay the bills...and more available to patients with cardiovascular diseases, especially for less expensive medicines, which which extend lives for many more years.
Pfizer has chosen to pay $43 billion for Seagen's cancer drugs...rather than 4 billon for Amarin's Vascepa...This may not have been a good move at this point in time..even taking into account Pfizer's multiple upcoming patent expirations.
Average ages in most countries are trending to be older...There are bound to be more patients ,needing care for acute and chronic diseases...As medical expenditures by governments become more restrictive, expensive medicines that extend lives for a few months or years, such as cancer therapies, will necessarily be made less available to patients by governments which pay the bills...and more available to patients with cardiovascular diseases, especially for less expensive medicines, which which extend lives for many more years.
Pfizer has chosen to pay $43 billion for Seagen's cancer drugs...rather than 4 billon for Amarin's Vascepa...This may not have been a good move at this point in time..even taking into account Pfizer's multiple upcoming patent expirations.
I'll admit that I'm not very knowledgeable in the ways that activist investors make money for themselves and for shareholders...I do feel, however, that prior Amarin management did not hold the interests of shareholders as one of their top priorities...That is why I voted with Denner in the proxy battle and I will vote with him again if he can achieve a BO of $4 billion or more.
CBB...QUOTE..."Amazing how much government money went into Covid vaccinations. Pfizer certainly cleaned up...Big Time!"
Pfizer certainly took a huge risk when they paid Biontech $2 Billion up front for Biontech's Covid Vaccine in the early stages of development...When the vaccine, which Pfizer later named Commiraty, proved successful in combating Covid, Pfizer deserved to be well compensated for taking that risk.
Now PFE is taking a much larger $43 billion risk by buying Seagan for ownership of their cancer drugs.
Innovation is about taking risks and being rewarded when the projects are successful...
Now, I hope PFE will take an exceedingly smaller risk by buying Amarin, with their already developed and proven effective drug, Vascepa, and then develop it into the global blockbuster it needs to be!
Nsleven...Thank you for posting this interesting case with Denner as a defendant...It is undeniable that strange things were happening in that case.
In the Amarin vs. Healthnet case, the outcome of which was of vital importance to Amarin, and which case has been settled... the terms of the settlement were suspiciously never disclosed to the shareholders by either PWO or by Denner...supposedly the reason for that failure was that the settlement terms forbade disclosure ...Whatever the reason, this is IMO unacceptable in a company owned by the public.
CBB...QUOTE..."Funny that BP has billions in cash available for acquisitions
and yet there is a government entity that can quash any deal they do not
want to go forward."
What is also funny is that as the courts are making it more difficult for small undercapitalized companies to innovate new drugs and recoup their expenses through patent exclusivity, government is making it difficult for BP to merge with smaller companies to defray the expenses inherent in innovating new drugs.
Government seems more interested in cheaper drugs for today than better drugs for tomorrow....Politicians seem to want to have it both ways..but...YOU CAN'T HAVE IT BOTH WAYS!
There is a break up fee of over $2 billion that PFE is contracted to pay Seagan if the FTC nixes their deal to acquire Seagan...as is becoming more likely....QUOTE..."Antitrust Fears Dampen Support for $43B Pfizer-Seagen Deal"
PFE could have easily bought Amarin for about $4 billion and owned Vascepa, a drug that has the potential to save more lives than all of Seagan's drugs.
Mar 14, 2023 — Pfizer has $43 billion riding on the acquisition...with a $2.224 billion “termination fee” it will have to pay Seagen should the PFE acquisition deal go sour.
Teva made the claim that a GSX win at the S.C. would bring on a rash of 'skinny label' law suits
The recent interpretation of the HW law by many courts is now the source of more law suits aimed at invalidating patents, with the purpose of paving the way for generic litigators to profit from 'skinny labels'...than it is the source of law suits over patent infringements due to the 'skinny labels', which resulted from those patent invalidations.
Do Teva's claim is false on its face.
Rose....Yes ! The generic companies are guilty of infringement...The usage figures are available to the generic company and they prove that the generic company has the intent to continue infringing.